CDK4/6 inhibitors in Breast Cancer Therapy examines the pivotal role of CDK4/6 inhibition in treating hormone receptor-positive (HR+)/HER2-negative advanced breast cancer. The book highlights FDA-approved applications of these inhibitors alongside endocrine therapy and explores ongoing research into their potential as neoadjuvant treatments. It provides insights into the drug discovery and development of CDK4/6 inhibitors, covering their molecular mechanisms, pharmacology, and clinical applications. Chapters address their use in mono and adjuvant therapies, as well as challenges in targeting, while also discussing market potential and post-marketing safety issues.
This book is a valuable resource for researchers and academics, enhancing understanding of CDK4/6 inhibitors' chemistry and therapeutic implications. By presenting detailed information on clinical trials and market formulations, it equips the audience with essential knowledge to navigate the complexities of targeted breast cancer therapies and contributes to advancing research in this critical area.
This book is a valuable resource for researchers and academics, enhancing understanding of CDK4/6 inhibitors' chemistry and therapeutic implications. By presenting detailed information on clinical trials and market formulations, it equips the audience with essential knowledge to navigate the complexities of targeted breast cancer therapies and contributes to advancing research in this critical area.
Table of Contents
1. CDK4/6 inhibitors: Drug discovery, development and classification2. CDK4/6 inhibitors: a medicinal chemistry, pharmacology, in-silico and drug delivery perspectives (SAR, LIGAND BINDING, SMALL MOLECULE, LIPINSKI RULE, PHYSICOCHEMICAL PROPERTIES)
3. Molecular mechanism and mechanism of action of CDK4/6 inhibitors
4. CDK4/6 inhibitors: clinical status, patent review and recent updates
5. The neoteric paradigm of the use of CDK4/6 for breast cancer treatment as mono and adjuvant therapy
6. The repurposing era of CDK4/6 in the treatment of various ailments
7. Cytotoxic profile, molecular modelling, cell cycle arrest and apoptotic induction induced by CDK4/6 inhibitors
8. The present-day means and challenges in the targeting of CDK4/6 inhibitors
9. Market potential and post-marketing safety challenges of CDK4/6 inhibitors
10. CDK4/6 inhibitors: future perspectives
